Two Early Trials Show Promise in Treating Deadly Brain Cancer

Two early trials have shown promise in treating glioblastoma, one of the deadliest types of cancer that affects the brain. Glioblastoma is known for its aggressive nature, low survival rate, and the lack of a cure.

The trials involved personalized immunotherapy known as CAR-T therapy, which targeted tumors in patients whose glioblastoma had returned after initial treatment. Both trials used CAR-T cells that were programmed to attack two targets simultaneously, with the hope of better equipping the cells to destroy solid tumors.

While the results of the trials showed promising temporary tumor shrinkage in patients, more research is needed to determine the long-term effectiveness of the treatment. Participants in the trials experienced side effects such as fever, vomiting, and neurological effects.

One trial involved injecting CAR-T cells directly into the cerebrospinal fluid, while the other delivered them locally into the brain. These trials build on previous research that suggests CAR-T therapy may be both safe and effective for glioblastoma.

Researchers are planning to continue with phase 1 trials and explore the best combination of treatments for glioblastoma in the future. The goal is to find a more effective and safer treatment option for patients battling this aggressive form of cancer.